Donald E. Bobo, Jr. Sells 25,000 Shares of Edwards Lifesciences Corporation (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald E. Bobo, Jr. sold 25,000 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $116.00, for a total value of $2,900,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Friday, July 28th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $114.68, for a total value of $607,804.00.
  • On Thursday, June 29th, Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $117.15, for a total value of $656,040.00.

Edwards Lifesciences Corporation (EW) opened at 116.26 on Thursday. The firm’s 50-day moving average price is $117.20 and its 200 day moving average price is $105.15. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75. The firm has a market capitalization of $24.55 billion, a P/E ratio of 35.26 and a beta of 0.63.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. The business had revenue of $842 million for the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.76 earnings per share. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/08/10/donald-e-bobo-jr-sells-25000-shares-of-edwards-lifesciences-corporation-nyseew-stock.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. South Texas Money Management Ltd. boosted its position in shares of Edwards Lifesciences Corporation by 157.9% in the first quarter. South Texas Money Management Ltd. now owns 344,816 shares of the medical research company’s stock worth $32,437,000 after buying an additional 211,119 shares during the period. Financial Counselors Inc. boosted its position in shares of Edwards Lifesciences Corporation by 2.1% in the first quarter. Financial Counselors Inc. now owns 13,637 shares of the medical research company’s stock worth $1,283,000 after buying an additional 282 shares during the period. American Century Companies Inc. boosted its position in shares of Edwards Lifesciences Corporation by 7.2% in the first quarter. American Century Companies Inc. now owns 2,046,875 shares of the medical research company’s stock worth $192,550,000 after buying an additional 137,934 shares during the period. Advisor Partners LLC boosted its position in shares of Edwards Lifesciences Corporation by 7.5% in the first quarter. Advisor Partners LLC now owns 4,895 shares of the medical research company’s stock worth $460,000 after buying an additional 341 shares during the period. Finally, Torch Wealth Management LLC bought a new position in shares of Edwards Lifesciences Corporation during the first quarter worth about $1,635,000. 84.15% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have commented on EW shares. Jefferies Group LLC restated a “buy” rating on shares of Edwards Lifesciences Corporation in a research note on Wednesday, April 26th. Vetr lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating and set a $124.67 price objective on the stock. in a research note on Monday, May 15th. Royal Bank Of Canada restated a “buy” rating on shares of Edwards Lifesciences Corporation in a research note on Tuesday, May 30th. Bank of America Corporation raised their price objective on Edwards Lifesciences Corporation from $120.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, May 30th. Finally, Zacks Investment Research upgraded Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 price objective on the stock in a research note on Monday, May 22nd. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $121.13.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply